Enhanced killing of melanoma cells by simultaneously targeting Mcl-1 and NOXA

Cancer Research

Volumn 66, Issue 19, 2006, Pages 9636-9645

  Qin, Jian Zhong ^a   Xin, Hong ^a   Sitailo, Leonid A ^a   Denning, Mitchell F ^a   Nickoloff, Brian J ^a  

^a LOYOLA UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BORTEZOMIB; FLUDARABINE; PROTEIN BAK; PROTEIN BAX; PROTEIN MCL 1; PROTEIN NOXA; SMALL INTERFERING RNA;

APOPTOSIS; ARTICLE; CELL DEATH; CONTROLLED STUDY; HUMAN; HUMAN CELL; MELANOMA; MELANOMA CELL; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN SECRETION; PROTEIN TARGETING; RNA INTERFERENCE; ULTRAVIOLET RADIATION;

ANTINEOPLASTIC AGENTS; APOPTOSIS; BCL-2 HOMOLOGOUS ANTAGONIST-KILLER PROTEIN; BCL-2-ASSOCIATED X PROTEIN; BORONIC ACIDS; CELL LINE, TUMOR; DRUG SCREENING ASSAYS, ANTITUMOR; DRUG SYNERGISM; HUMANS; MELANOMA; NEOPLASM PROTEINS; PROTEASE INHIBITORS; PROTEIN INTERACTION MAPPING; PROTO-ONCOGENE PROTEINS C-BCL-2; PYRAZINES; RNA, SMALL INTERFERING; ULTRAVIOLET RAYS; VIDARABINE;

EID: 33750312678     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-06-0747     Document Type: Article

References (58)

1. Jemal A, Thomas A, Murray T, Thun M. Cancer statistics, 2002. CA Cancer J Clin 2002;52:23-47.
2. Soengas MS, Lowe SW. Apoptosis and melanoma chemoresistance. Oncogene 2003;22:3138-51.
3. Chang AE, Karnell LH, Menck HR. The National Cancer Data Base report on cutaneous and noncutaneous melanoma: a summary of 84,836 cases from the past decade. The American College of Surgeons Commission on Cancer and the American Cancer Society. Cancer 1998;83:1664-78.
4. Grossman D, Kim PJ, Schechner JS, Altieri DC. Inhibition of melanoma tumor growth in vivo by survivin targeting. Proc Natl Acad Sci U S A 2001;98:635-40.
5. Helmbach H, Rossmann E, Kern MA, Schadendorf D. Drug-resistance in human melanoma. Int J Cancer 2001;93:617-22.
6. Mandara M, Nortilli R, Sava T, Cetto GL. Chemotherapy for metastatic melanoma. Expert Rev Anticancer Ther 2006;6:121-30.
7. Chin L, Merlino G, DePinho RA. Malignant melanoma: modern black plague and genetic black box. Genes Dev 1998;12:3467-81.
8. Grossman D, Altieri DC. Drug resistance in melanoma: mechanisms, apoptosis, and new potential therapeutic targets. Cancer Metastasis Rev 2001;20:3-11.
9. Hussein MR, Haemel AK, Wood GS. Apoptosis and melanoma: molecular mechanisms. J Pathol 2003;199:275-88.
10. Tron VA, Krajewski S, Klein-Parker H, et al. Immunohistochemical analysis of Bcl-2 protein regulation in cutaneous melanoma. Am J Pathol 1995;146:643-50.
11. Fernandez Y, Verhaegen M, Miller TP, et al. Differential regulation of noxa in normal melanocytes and melanoma cells by proteasome inhibition: therapeutic implications. Cancer Res 2005;65:6294-304.
12. Qin JZ, Stennett L, Bacon P, et al. p53-independent NOXA induction overcomes apoptotic resistance of malignant melanomas. Mol Cancer Ther 2004;3:895-902.
13. Qin JZ, Ziffra J, Stennett L, et al. Proteasome inhibitors trigger NOXA-mediated apoptosis in melanoma and myeloma cells. Cancer Res 2005;65:6282-93.
14. Dalton WS. The proteasome. Semin Oncol 2004;31:3-9.
15. Satyamoorthy K, Bogenrieder T, Herlyn M. No longer a molecular black box-new clues to apoptosis and drug resistance in melanoma. Trends Mol Med 2001;7:191-4.
16. Chudnovsky Y, Khavari PA, Adams AE. Melanoma genetics and the development of rational therapeutics. J Clin Invest 2005;115:813-24.
17. Amiri KI, Horton LW, LaFleur BJ, Sosman JA, Richmond A. Augmenting chemosensitivity of malignant melanoma tumors via proteasome inhibition: implication for bortezomib (Velcade, PS-341) as a therapeutic agent for malignant melanoma. Cancer Res 2004;64:4912-8.
18. Markovic SN, Geyer SM, Dawkins F, et al. A phase II study of bortezomib in the treatment of metastatic malignant melanoma. Cancer 2005;103:2584-9.
19. Green DR, Kroemer G. The pathophysiology of mitochondrial cell death. Science 2004;305:626-9.
20. Huang DC, Strasser A. BH3-only proteins-essential initiators of apoptotic cell death. Cell 2000;103:839-42.
21. Strasser A. The role of BH3-only proteins in the immune system. Nat Rev Immunol 2005;5:189-200.
22. Gelinas C, White E. BH3-only proteins in control: specificity regulates MCL-1 and BAK-mediated apoptosis. Genes Dev 2005;19:1263-8.
23. Lindsten T, Ross AJ, King A, et al. The combined functions of proapoptotic Bcl-2 family members bak and bax are essential for normal development of multiple tissues. Mol Cell 2000;6:1389-99.
24. Chen L, Willis SN, Wei A, et al. Differential targeting of prosurvival Bcl-2 proteins by their BH3-only ligands allows complementary apoptotic function. Mol Cell 2005;17:393-403.
25. Willis SN, Chen L, Dewson G, et al. Proapoptotic Bak is sequestered by Mcl-1 and Bcl-xL, but not Bcl-2, until displaced by BH3-only proteins. Genes Dev 2005;19:1294-305.
26. Lang-Rollin I, Maniati M, Jabado O, et al. Apoptosis and the conformational change of Bax induced by proteasomal inhibition of PC12 cells are inhibited by bcl-xL and bcl-2. Apoptosis 2005;10:809-20.
27. Panaretakis T, Pokrovskaja K, Shoshan MC, Grander D. Activation of Bak, Bax, and BH3-only proteins in the apoptotic response to doxorubicin. J Biol Chem 2002;277:44317-26.
28. von Haefen C, Gillissen B, Hemmati PG, et al. Multidomain Bcl-2 homolog Bax but not Bak mediates synergistic induction of apoptosis by TRAIL and 5-FU through the mitochondrial apoptosis pathway. Oncogene 2004;23:8320-32.
29. Iglesias-Serret D, Pique M, Gil J, Pons G, Lopez JM. Transcriptional and translational control of Mcl-1 during apoptosis. Arch Biochem Biophys 2003;417:141-52.
30. Chaturvedi V, Sitailo LA, Qin JZ, et al. Knockdown of p53 levels in human keratinocytes accelerates Mcl-1 and Bcl-x(L) reduction thereby enhancing UV-light induced apoptosis. Oncogene 2005;24:5299-312.
31. Maggio SC, Rosato RR, Kramer LB, et al. The histone deacetylase inhibitor MS-275 interacts synergistically with fludarabine to induce apoptosis in human leukemia cells. Cancer Res 2004;64:2590-600.
32. Robak T, Korycka A, Kasznicki M, Wrzesien-Kus A, Smolewski P. Purine nucleoside analogues for the treatment of hematological malignancies: pharmacology and clinical applications. Curr Cancer Drug Targets 2005;5:421-44.
33. Duechler M, Linke A, Cebula B, et al. In vitro cytotoxic effect of proteasome inhibitor bortezomib in combination with purine nucleoside analogues on chronic lymphocytic leukaemia cells. Eur J Haematol 2005;74:407-17.
34. Armstrong JS. Mitochondria: a target for cancer therapy. Br J Pharmacol 2005;147:239-48.
35. Griffiths GJ, Dubrez L, Morgan CP, et al. Cell damage-induced conformational changes of the pro-apoptotic protein Bak in vivo precede the onset of apoptosis. J Cell Biol 1999;144:903-14.
36. Nechushtan A, Smith CL, Hsu YT, Youle RJ, Conformation of the Bax C-terminus regulates subcellular location and cell death. EMBO J 1999;18:2330-41.
37. Qin JZ, Bacon P, Panella J, et al. Low-dose UV-radiation sensitizes keratinocytes to TRAIL-induced apoptosis. J Cell Physiol 2004;200:155-66.
38. Sitailo LA, Tibudan SS, Denning MF. Bax activation and induction of apoptosis in human keratinocytes by the protein kinase Cδ catalytic domain. J Invest Dermatol 2004;123:434-43.
39. Wei MC, Zong WX, Cheng EH, et al. Proapoptotic BAX and BAK: a requisite gateway to mitochondrial dysfunction and death. Science 2001;292:727-30.
40. Nijhawan D, Fang M, Traer E, et al. Elimination of Mcl-1 is required for the initiation of apoptosis following ultraviolet irradiation. Genes Dev 2003;17:1475-86.
41. Battle TE, Arbiser J, Frank DA. The natural product honokiol induces caspase-dependent apoptosis in B-cell chronic lymphocytic leukemia (B-CLL) cells. Blood 2005;106:690-7.
42. Ma Y, Cress WD, Haura EB. Flavopiridol-induced apoptosis is mediated through up-regulation of E2F1 and repression of Mcl-1. Mol Cancer Ther 2003;2:73-81.
43. Adams J. The proteasome: a suitable antineoplastic target. Nat Rev Cancer 2004;4:349-60.
44. Dalton W. Drug resistance in hematologic malignancies. Clin Adv Hematol Oncol 2005;3:267-8.
45. Danial NN, Korsmeyer SJ. Cell death: critical control points. Cell 2004;116:205-19.
46. Reed JC. Apoptosis-targeted therapies for cancer. Cancer Cell 2003;3:17-22.
47. Strasser A, O'Connor L, Dixit VM. Apoptosis signaling. Annu Rev Biochem 2000;69:217-45.
48. Shore GC, Viallet J. Modulating the bcl-2 family of apoptosis suppressors for potential therapeutic benefit in cancer. Am Soc Hematol Educ Program 2005;226-30.
49. Sun W, Schuchter LM. Metastatic melanoma. Curr Treat Options Oncol 2001;2:193-202.
50. Borner C, Schlagbauer Wadl H, Fellay I, et al. Mutated N-ras upregulates Bcl-2 in human melanoma in vitro and in SCID mice. Melanoma Res 1999;9:347-50.
51. Davies H, Bignell GR, Cox C, et al. Mutations of the BRAF gene in human cancer. Nature 2002;417:949-54.
52. Grossman D, McNiff JM, Li F, Altieri DC. Expression and targeting of the apoptosis inhibitor, survivin, in human melanoma. J Invest Dermatol 1999;113:1076-81.
53. Hersey P, Zhang XD. How melanoma cells evade trail-induced apoptosis. Nat Rev Cancer 2001;1:142-50.
54. Ivanov VN, Bhoumik A, Ronai Z. Death receptors and melanoma resistance to apoptosis. Oncogene 2003;22:3152-61.
55. Allen JD, Zhang XD, Scott CL, et al. Is Apaf-1 expression frequently abrogated in melanoma? Cell Death Differ 2005;12:680-1.
56. Peltenburg LT, de Bruin EC, Meersma D, et al. Expression and function of the apoptosis effector Apaf-1 in melanoma. Cell Death Differ 2005;12:678-9.
57. Soengas MS, Capodieci P, Polsky D, et al. Inactivation of the apoptosis effector Apaf-1 in malignant melanoma. Nature 2001;409:207-11.
58. Fernandez Y, Miller TP, Denoyelle C, et al. Chemical blockage of the proteasome inhibitory function of bortezomib: impact on tumor cell death. J Biol Chem 2006;281:1107-18.